Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GNPX |
---|---|---|
09:48 ET | 100 | 2.54 |
09:50 ET | 200 | 2.5 |
09:56 ET | 100 | 2.51 |
09:57 ET | 100 | 2.51 |
10:01 ET | 1800 | 2.5 |
10:14 ET | 5062 | 2.5 |
10:26 ET | 100 | 2.43 |
10:37 ET | 600 | 2.43 |
10:39 ET | 221 | 2.4343 |
11:00 ET | 100 | 2.475 |
11:04 ET | 1000 | 2.5 |
11:08 ET | 100 | 2.46 |
11:29 ET | 100 | 2.46 |
11:38 ET | 100 | 2.48 |
11:44 ET | 600 | 2.4814 |
12:03 ET | 100 | 2.46 |
12:27 ET | 5564 | 2.4964 |
12:36 ET | 100 | 2.5799 |
12:43 ET | 900 | 2.56 |
01:14 ET | 1732 | 2.47 |
01:33 ET | 1662 | 2.484 |
02:00 ET | 534 | 2.5599 |
02:02 ET | 100 | 2.49 |
02:08 ET | 100 | 2.56 |
02:15 ET | 500 | 2.5268 |
02:18 ET | 314 | 2.49 |
02:31 ET | 100 | 2.525 |
02:36 ET | 120 | 2.548 |
02:38 ET | 100 | 2.48 |
02:40 ET | 400 | 2.5076 |
03:14 ET | 2000 | 2.46 |
03:18 ET | 771 | 2.45 |
03:21 ET | 200 | 2.47 |
03:41 ET | 200 | 2.43 |
03:43 ET | 5000 | 2.4999 |
03:48 ET | 6206 | 2.5119 |
03:50 ET | 4014 | 2.5599 |
03:52 ET | 100 | 2.44 |
03:59 ET | 100 | 2.505 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Genprex Inc | 5.4M | -0.1x | --- |
CeCors Inc | 5.4M | 0.0x | --- |
Protagenic Therapeutics Inc | 5.5M | -1.2x | --- |
ProtoKinetix Inc | 5.2M | -13.5x | --- |
Portage Biotech Inc | 5.2M | 0.0x | --- |
Synaptogenix Inc | 5.2M | -0.1x | --- |
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.59 |
EPS | $-22.93 |
Book Value | $4.99 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.